<DOC>
	<DOCNO>NCT00873509</DOCNO>
	<brief_summary>The purpose study evaluate effect twice-daily oral buspirone core feature autism autistic child age 2-6 year measure change baseline Autism Diagnostic Observation Schedule ( ADOS ) Composite Total score compare placebo 6 month .</brief_summary>
	<brief_title>Buspirone Treatment 2-6 Year Old Children With Autistic Disorder</brief_title>
	<detailed_description>This multi-center , randomize , placebo-controlled , double-masked study 166 evaluable participant take buspirone twice daily 6 month . Children age 2-6 year autism randomize receive one three treatment : 2.5mg , 5.0mg , match placebo . The placebo control trial follow optional follow-up trial ass long term safety buspirone . In addition , PET scan serotonin synthesis plasma serotonin measure baseline determine whether measure predictor drug response . This trial aim core feature autism . The outcome measure efficacy examiner parent rating psychological test questionnaire . The outcome measure primary objective Autism Diagnostic Observation Scale ( ADOS ) Composite Total score . The behavioral outcome secondary aim delineate study design .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Participants : must meet study definition diagnosis autistic disorder determine clinical diagnosis base upon DSMIV criterion , Autism Diagnostic InterviewRevised ( ADIR ) Autism Diagnostic Observation Schedule ( ADOS ) perform baseline 1 . ADIR conduct trained study staff Baseline 1 Visit . If participant ADIR past 12 month , accept provided person administer score test site personnel validate study . Age 2 less 6 year , male female . Parent/Legal Guardian/Caregiver must able understand , read speak English Written Informed Consent . Presence history neurological disorder , include seizure disorder ( abnormal EEG without seizure exclude ) , PKU , tuberous sclerosis , Rett syndrome , Fragile X syndrome , Down Syndrome traumatic brain injury . Other medical behavioral problem require medication centrally active . Clinical laboratory evidence renal hepatic disease ( SGPT , GGT &gt; 2 x normal value , serum creatinine &gt; 1.5 x normal value ) . Treatment medication know alter activity CYP3A4 enzyme include ketoconazole , itraconazole , grapefruit juice , erythromycin , clarithromycin , cimetidine , verapamil , diltiazem , rifampin , phenytoin , phenobarbital , carbamazepine within previous 2 month duration study prohibit . Use centrally act drug 6 week prior study . These drug include limited neuroleptic , benzodiazepine , anticonvulsant antidepressant . Shorter time may consider depend half life drug . Prior treatment period longer two week buspirone selective serotonin reuptake inhibitor . This include herbal substance St John 's Wort similar pharmacological action . Known allergy study medication . Unable provide require blood sample .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Autism</keyword>
</DOC>